A passionate advocate for patients with cancer and other serious diseases, Terry Wilcox is Executive Director of Patients Rising, a non-profit patient education and advocacy organization that helps patients get access to essential diagnostics and the treatments they need.
To bring cross-agency clinical leaders together, the FDA should establish a Center of Excellence for Rare Diseases. This would bring together specialized staff and resources from multiple review divisions to leverage their expertise about different bodily systems, trial designs, pharmacology, and other specialized fields.
The major healthcare players have no incentive to bring costs down. Insurers, pharmacy benefit managers, and other healthcare interests profit by charging higher and higher rates. However, one entity has the scale and incentive to meaningfully lower costs: employer health plans.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Covering travel expenses is not an act of altruism for employers. It's in their financial interest to have their workforce access the specialized care they need to feel better rather than consigning them to an inadequate care treadmill at the local hospital.
Insurers’ abuse of prior authorization is creating health risks for patients and contributing to higher downstream costs for both beneficiaries and the larger health care system.